HGF and breast cancer: Apparently, HVS treatment significantly suppressed HGF-induced mammary tumor cell migration in a dose-dependent manner, with an IC50 value of 2.5 μM, demonstrating three-fold improvement versus its parent (−)-oleocanthal (IC50 8.5 μM, Figure 5A, Table 1).